228 related articles for article (PubMed ID: 25150193)
1. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports.
Schroll JB; Abdel-Sattar M; Bero L
J Clin Epidemiol; 2015 Jan; 68(1):102-7. PubMed ID: 25150193
[TBL] [Abstract][Full Text] [Related]
2. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
3. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
[TBL] [Abstract][Full Text] [Related]
4. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
5. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
6. Canadian, European and United States new drug approval times now relatively similar.
Rawson NSB
Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
[TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
[TBL] [Abstract][Full Text] [Related]
8. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
9. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
Lexchin J
PLoS One; 2023; 18(6):e0286802. PubMed ID: 37319240
[TBL] [Abstract][Full Text] [Related]
10. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
[TBL] [Abstract][Full Text] [Related]
11. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
[TBL] [Abstract][Full Text] [Related]
12. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006-2015: a cohort study.
Boucaud-Maitre D; Altman JJ
Eur J Clin Pharmacol; 2016 Oct; 72(10):1275-1281. PubMed ID: 27473682
[TBL] [Abstract][Full Text] [Related]
13. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
14. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews.
McDonagh MS; Peterson K; Balshem H; Helfand M
J Clin Epidemiol; 2013 Oct; 66(10):1071-81. PubMed ID: 23856190
[TBL] [Abstract][Full Text] [Related]
15. Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA.
Hiayev S; Shacham-Shmueli E; Berkovitch M; Weiss I; Ashkenazi S; Vexberg MH; Hershkowitz R; Gorelik E; Mayan H; Steinmetz Y; Yanai NB; Schlissel O; Azem M; Gutgold N; Shulman K; Divinsky M; Yarom N; Vishkautzan A; Ganzel C; Gatt ME; Arcavi L; Marom E; Uziely B; Zevin S; Meirow H; Luxenburg O; Ainbinder D
BMJ Open; 2023 May; 13(5):e067313. PubMed ID: 37142315
[TBL] [Abstract][Full Text] [Related]
16. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
17. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
Hart B; Lundh A; Bero L
BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
[TBL] [Abstract][Full Text] [Related]
18. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
[TBL] [Abstract][Full Text] [Related]
19. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
20. Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals.
Pinto CA; Balantac Z; Mt-Isa S; Liu X; Bracco OL; Clarke H; Tervonen T
Drug Discov Today; 2023 Oct; 28(10):103719. PubMed ID: 37467877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
